X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
1. K2hpo4
2. Kd2po4
3. Potassium Acid Phosphate
4. Potassium Dideuterium Phosphate
5. Potassium Dihydrogen Phosphate
6. Potassium Monohydrogen Phosphate
7. Potassium Phosphate
8. Potassium Phosphate (k-h2po4)
9. Potassium Phosphate (k-h3po4(1:2))
10. Potassium Phosphate (k2-hpo4)
11. Potassium Phosphate (k3-po4)
12. Potassium Phosphate, Dibasic
13. Potassium Phosphate, Monobasic
14. Potassium Phosphate, Unspecified Form
1. 7758-11-4
2. Dipotassium Phosphate
3. Potassium Phosphate Dibasic
4. Dipotassium Hydrogenphosphate
5. Dibasic Potassium Phosphate
6. Potassium Hydrogen Phosphate
7. Potassium Phosphate, Dibasic
8. Phosphoric Acid, Dipotassium Salt
9. Potassium Dibasic Phosphate
10. Dipotassium Monophosphate
11. Potassium Monohydrogen Phosphate
12. K2hpo4
13. Potassium Monophosphate
14. Dipotassium Hydrogenorthophosphate
15. Dipotassium Monohydrogen Phosphate
16. Dipotassium Orthophosphate
17. Mfcd00011383
18. Hydrogen Dipotassium Phosphate
19. Potassium Phosphate (dibasic)
20. Di-potassium Hydrogen Phosphate
21. Dipotassium Hydrogen Orthophosphate
22. Sec.-potassium Phosphate
23. Dipotassium Acid Phosphate
24. Potassium Hydrogenphosphate
25. Phosphoric Acid, Potassium Salt (1:2)
26. Secondary Potassium Phosphate
27. Ci71s98n1z
28. Ins No.340(ii)
29. Ins-340(ii)
30. Dipotassium Hydrogen Monophosphate
31. E-340(ii)
32. Potassium Phosphate Dibasic, Acs Reagent
33. Isolyte
34. Dipotassium-o-phosphate
35. Dipotassium;hydrogen Phosphate
36. Ccris 6544
37. Hsdb 935
38. Kali Phosphoricum
39. Leex-a-phos
40. Einecs 231-834-5
41. Mediject P (tn)
42. Di Potassium Phosphate
43. Potassiumhydrogenphosphate
44. Potassium Phosphate,dibasic
45. Dipotasium Hydrogen Phosphate
46. Unii-ci71s98n1z
47. Potassium Monohydrogenphosphate
48. Potassium Hydrogen Monophosphate
49. Chembl1200459
50. Dtxsid8035506
51. Kali Phosphoricum [hpus]
52. Chebi:32031
53. Chebi:131527
54. Dipotassium Phosphate [inci]
55. Dipotassium Monohydrogen Orthophosphate
56. Potassium Dibasic Phosphate Trihydrate
57. Potassium Phosphate (k2hpo4)
58. Akos015915872
59. Akos016371887
60. Db09414
61. Potassium Hydrogen Phosphate, Anhydrous
62. Potassium Phosphate [green Book]
63. Potassium Phosphate, Dibasic, Anhydrous
64. Potassium Phosphate, Dibasic (jan/usp)
65. Potassium Phosphate, Dibasic [usp:jan]
66. Potassium Phosphate Dibasic, Lr, >=98%
67. Potassium Phosphate, Dibasic [ii]
68. Potassium Phosphate, Dibasic [mi]
69. Sy010082
70. Di-potassium Hydrogen Orthophosphate
71. Dipotassium Phosphate [ep Impurity]
72. Potassium Phosphate, Dibasic [fcc]
73. Potassium Phosphate, Dibasic [jan]
74. Potassium Phosphate,dibasic [vandf]
75. Dipotassium Phosphate [ep Monograph]
76. Potassium Phosphate Dibasic Anhydrate
77. Potassium Phosphate, Dibasic [hsdb]
78. Dibasic Potassium Phosphate [usp-rs]
79. Potassium Phosphate Dibasic [who-dd]
80. Potassium Phosphate Dibasic Solution, 1.0 M
81. Potassium Phosphate Dibasic, Biochemical Grade
82. Potassium Phosphate Dibasic, Puriss., >=99%
83. D02403
84. Dipotassium Hydrogen Phosphate (k2hpo4)
85. Ec 231-834-5
86. Dibasic Potassium Phosphate [usp Impurity]
87. Dibasic Potassium Phosphate [usp Monograph]
88. Potassium Phosphate Dibasic, Acs Reagent, >=98%
89. Potassium Phosphate Dibasic, Usp, 98.0-100.5%
90. Potassium Phosphate, Dibasic [orange Book]
91. Q403721
92. Potassium Phosphate Dibasic, Ar, Anhydrous, >=99%
93. Potassium Phosphate, Dibasic [usp Impurity]
94. Potassium Phosphate Dibasic, Reagent Grade, >=98.0%
95. Potassium Phosphate Dibasic, 99.95% Trace Metals Basis
96. Potassium Phosphate Dibasic, Saj First Grade, >=98.0%
97. Potassium Phosphate Dibasic, Trace Metals Grade 99.95%
98. Potassium Phosphate Dibasic, Jis Special Grade, >=99.0%
99. Potassium Phosphate Dibasic, Vetec(tm) Reagent Grade, 98%
100. Potassium Phosphate Dibasic, Meets Usp Testing Specifications
101. Dibasic Potassium Phosphate Component Of Potassium Phosphates
102. Potassium Phosphates Component Dibasic Potassium Phosphate
103. Dibasic Potassium Phosphate, United States Pharmacopeia (usp) Reference Standard
104. Potassium Phosphate Dibasic, Anhydrous, Free-flowing, Redi-dri(tm), Acs Reagent, >=98%
105. Potassium Phosphate Dibasic, Puriss. P.a., Acs Reagent, Anhydrous, >=99.0% (t)
106. Potassium Phosphate Dibasic Anhydrous, Pharmagrade, Usp, Manufactured Under Appropriate Gmp Controls For Pharma Or Biopharmaceutical Production.
107. Potassium Phosphate Dibasic, Anhydrous, For Luminescence, For Molecular Biology, Bioultra, >=99.0% (t)
| Molecular Weight | 174.176 g/mol |
|---|---|
| Molecular Formula | HK2O4P |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 0 |
| Exact Mass | 173.88865848 g/mol |
| Monoisotopic Mass | 173.88865848 g/mol |
| Topological Polar Surface Area | 83.4 Ų |
| Heavy Atom Count | 7 |
| Formal Charge | 0 |
| Complexity | 46.5 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
CATHARTIC
Budavari, S. (ed.). The Merck Index - Encyclopedia of Chemicals, Drugs and Biologicals. Rahway, NJ: Merck and Co., Inc., 1989., p. 1216
Factors affecting calcium-phosphate solubility in parenteral nutrition solutions used in neonates were studied. Six neonatal parenteral nutrition solutions were prepared using either Aminosyn or FreAmine II and various amino acid and dextrose concentrations. Phosphorus (as mono- and dibasic potassium phosphate) and calcium (as 10% calcium gluconate) were added in concentrations of calcium 2.5-100 meq/l and phosphorus 2.5-100 mmol/l. Duplicate samples were prepared and analyzed either after they were heated in a water bath (37 C) for 20 min or after 18 hr at 25 C followed by 30 min in a water bath (37 C). Precipitation was detected visually and spectrophotometrically, and pH was measured. Lipid emulsion was added to 2 FreAmine II solutions in a ratio of 7.5:1 (parenteral nutrition solution:lipid) and the resulting pH was measured. Time and temperature affected calcium-phosphate solubility in all solutions tested. Precipitation curves of amount of calcium versus amount of phosphate added were prepared for each solution. Amino acid and dextrose concentrations affected the pH of the solutions, and when a lipid emulsion was added, the pH rose more in the 1% than in the 2% FreAmine II solution. In selected solutions, as much as 120 mg/kg/day calcium and 55 mg/kg/day phosphate can be administered, approximating daily third trimester accumulation of these minerals. Use of the precipitation curves in this paper, with attention to their limitations, should aid in the safe delivery of calcium and phosphorus IV to neonates.
PMID:6798868 Eggert LD et al; Am J Hosp Pharm 39 (Jan): 49-53 (1982)
SALINE BULK CATHARTIC
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 744
Oral administration is safer, but careful monitoring of serum electrolyte levels and renal function is necessary. Nausea, vomiting, and diarrhea may occur and may be dose dependent. Concomitant use of antacids containing aluminum and/or magnesium should be avoided, because they may bind phosphate and prevent it absorption (calcium antacids also may bind phosphate, and it is assumed that these agents are not given to hypercalcemic patients).
American Medical Association, Department of Drugs. Drug Evaluations. 6th ed. Chicago, Ill: American Medical Association, 1986., p. 897
Phosphate should not be given to patients with impaired renal function or hyperphosphatemia. They should not be given to patients with alkaline urine due to urinary tract infections because increased calcium and phosphate concentrations in the alkaline urine increase the risk of calcium phosphate stones.
American Medical Association, Department of Drugs. Drug Evaluations. 6th ed. Chicago, Ill: American Medical Association, 1986., p. 897
Intravenous administration of phosphates is dangerous. Hypocalcemia, hypotension and shock, myocardial infarction, tetany, and acute renal failure have occurred, and deaths have been reported. Deposition of calcium phosphate in the kidney, heart, lung, and blood vessels also may be fatal. For these reasons, intravenous therapy is not justified in the treatment of hypercalcemia. Phosphates should not be administered to patients with impaired renal function or hyperphosphatemia. They also should not be given to patients with alkaline urine due to urinary tract infections because increased calcium and phosphate concentrations in the alkaline urine increase the risk of calcium phosphate stones. Phosphate should be given as the potassium rather than the sodium salt because the latter causes volume expansion and inhibits phosphate reabsorption, thus negating the therapeutic effect. /Phosphate salt/
American Medical Association. AMA Drug Evaluations Annual 1991. Chicago, IL: American Medical Association, 1991., p. 1951
The most common adverse effect of phosphate salts is diarrhea. Patients with kidney stones may pass old stones when phosphate therapy is started and should be warned of this possibility. Phosphates are contraindicated in patients with infected stones and in those with renal function less than 30% of normal. /Orthophosphates/
American Medical Association, Department of Drugs. Drug Evaluations. 6th ed. Chicago, Ill: American Medical Association, 1986., p. 584
Dipotassium phosphate is used in imitation dairy creamers, dry powder beverages, mineral supplements, and starter cultures as an additive. It is used in non-dairy creamers to prevent coagulation. Dipotassium phosphate is also used to make buffer solutions and it is used in the production of trypticase soy agar which is used to make agar plates for culturing bacteria.
Phosphate is a major intracellular anion which participates in providing energy for metabolism of substances and contributes to important metabolic and enzymatic reactions in almost all organs and tissues. Phosphate exerts a modifying influence on calcium concentrations, a buffering effect on acid-base equilibrium, and has a major role in the renal excretion of hydrogen ions.
Cariostatic Agents
Substances that inhibit or arrest DENTAL CARIES formation. (Boucher's Clinical Dental Terminology, 4th ed) (See all compounds classified as Cariostatic Agents.)
Buffers
A chemical system that functions to control the levels of specific ions in solution. When the level of hydrogen ion in solution is controlled the system is called a pH buffer. (See all compounds classified as Buffers.)
Absorption
Potassium salts are well absorbed from gastro intestinal tract. Net phosphorus absorption may occur in the small intestine in some species but is primarily a function of the colon in horses.
Route of Elimination
Potassium is excreted primarily by kidney.
Volume of Distribution
Distribution is largely intracellular, but it is the intravascular concentration that is primarily responsible for toxicity.
Clearance
Phosphates are rapidly cleared by dialysis.
POTASSIUM SALTS ARE WELL ABSORBED FROM THE GASTROINTESTINAL TRACT. ... POTASSIUM IS EXCRETED PRIMARILY BY THE KIDNEY. /POTASSIUM SALTS/
McEvoy, G.K. (ed.). AHFS Drug Information 90. Bethesda, MD: American Society of Hospital Pharmacists, Inc., 1990 (Plus Supplements 1990)., p. 1425
Net phosphorus absorption may occur in the small intestine in some species but is primarily a function of the colon in horses. /SRP: Phosphates/
Booth, N.H., L.E. McDonald (eds.). Veterinary Pharmacology and Therapeutics. 5th ed. Ames, Iowa: Iowa State University Press, 1982., p. 640
/Ortho/ phosphate is absorbed from, and to a limited extent secreted into, the gastrointestinal tract. Transport of phosphate from the gut lumen is an active, energy-dependent process that is modified by several factors. ... Vitamin D stimulates phosphate absorption, an effect reported to precede its action on calcium ion transport. In adults, about two thirds of the ingested phosphate is absorbed, and that which is absorbed is almost entirely excreted into the urine. In growing children, phosphate balance is positive. Concentrations of phosphate in plasma are higher in children than in adults. This "hyperphosphatemia" decreases the affinity of hemoglobin for oxygen and is hypothesized to explain the physiological "anemia" of childhood. /Phosphates/
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1524
Phosphate is a major intracellular anion which participates in providing energy for metabolism of substances and contributes to important metabolic and enzymatic reactions in almost all organs and tissues.
In healthy children with phosphate overdose, half-life was 4.8 to 10.6 hours, and was prolonged to 17 hours in a child with renal insufficiency.
Once phosphate gains access to the body fluids and tissues, it exerts little pharmacological effect. If the ion is introduced into the intestine, the absorbed phosphate is rapidly excreted. If large amounts are given by this route, much of it may escape absorption. Because this property leads to a cathartic action, phosphate salts are employed as mild laxatives.
Once phosphate gains access to the body fluids and tissues, it exerts little pharmacological effect. If the ion is introduced into the intestine, the absorbed phosphate is rapidly excreted. If large amounts are given by this route, much of it may escape absorption. Because this property leads to a cathartic action, phosphate salts are employed as mild laxatives. Inorganic phosphate poisoning following ingestion of laxatives that contain phosphate salts has been reported in adults and children. Ingestion of large amounts of sodium dihydrogen phosphate lowers urinary pH. If excessive phosphate salts are introduced intravenously or orally, they may prove toxic by reducing the concentration of Ca 2+ in the circulation and from the precipitation of calcium phosphate in soft tissues. /Phosphates/
Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 1525
Market Place
